NASDAQ:INDV
Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc.'s revenue grew 4.3% in fiscal 2025 to $1.2B while operating margin rose to 21.1%, its highest in 4 years. Free cash flow was −$93.0M, −7.5% of revenue, and the diluted share count fell 3.8%.Summary generated from Indivior Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.2B
Revenue growth+4.3%
Revenue, 5-yr CAGRn/a
Gross margin80.2%
Operating margin21.1%
Net margin16.9%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$93.0M
FCF margin−7.5%
Share count change−3.8%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 901 | 1,093 | 1,188 | 1,239 |
| Operating income | −81 | −152 | 38 | 262 |
| Net income | −44 | −126 | 7 | 210 |
| Free cash flow | −9 | −308 | 7 | −93 |
Recent filings
- 8-KOther events
Oct 6, 2026 - 8-KRegulation FD disclosure
Sep 17, 2026 - 8-KTermination of a material agreement
Sep 15, 2026 - 4Insider transaction report
Aug 27, 2026 - 4Insider transaction report
Aug 5, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 3, 2026 - 8-KRegulation FD disclosure
Aug 3, 2026 - 8-KResults of operations and financial condition
Aug 3, 2026